Just a quick, permanent reminder for everyone following along. The brands we discuss may offer affiliate compensation or discounts on research products and materials. However: Everything we write — research summaries, interpretations, opinions, and any product commentary — is developed completely independently by the ELEVATE research community. No brand, manufacturer, or supplier reviews, approves, edits, or directs any of it. Ever. In fact, the opposite is frequently true. If anyone makes a statement about a product on this page, that statement is solely the view of the independent researcher who posted it. It is never the claim, position, endorsement or representation of any manufacturer, supplier, or brand. The compounds discussed here are research chemicals intended strictly for laboratory and research use only. They are not for human consumption. Any discussion of published studies, mechanisms, results, or product graphics is purely educational and informational. None of it constitutes medical advice, nor is it a recommendation, suggestion, or endorsement of non-research human use. All statements on this page reflect our independent research community’s analysis only. Variables exist in every research setting. Never treat any post, thread, graphic, or comment as the manufacturer’s position or as guidance for personal use. Appreciate y’all. Keep on researching.

Why did ReviveRx have to start sending reconstituted HcG? The 30ml bac water always came in clutch lol

Modafinil: What the Research Shows elevateresearch.blog/2026/10…

Elamipretide (SS-31): What the Research Shows elevateresearch.blog/2026/10…

For years, one of the most widely repeated claims in neuroscience was that humans stop producing new neurons after childhood. That position has become increasingly difficult to defend. Recent research suggests that neural progenitor cells persist in the adult human hippocampus, potentially even into old age. But the scientific debate is more complicated than simply declaring that adults grow new brain cells. Here’s how the evidence developed. 2018 — The controversy Sorrells et al., published in Nature, reported that hippocampal neurogenesis declined sharply during childhood and became undetectable in adults. That same year, Boldrini et al., publishing in Cell Stem Cell, examined brain tissue from 28 individuals aged 14–79. They identified thousands of immature neurons across the age range. Two respected research groups. Two dramatically different conclusions. 2019 — Tissue preservation changes the picture Moreno-Jiménez et al., Nature Medicine, examined hippocampal tissue using carefully controlled preservation methods. They identified thousands of immature neurons in neurologically healthy individuals up to age 87. Interestingly, the number of immature neurons declined substantially in Alzheimer’s disease. This suggested that differences in tissue handling might explain some earlier conflicting findings. 2025 — Stronger evidence emerges Researchers at Sweden’s Karolinska Institutet, led by Jonas Frisén’s group, published findings in Science. Using single-nucleus RNA sequencing and machine-learning approaches, they investigated human hippocampal tissue spanning infancy through age 78. They identified neural progenitor populations, including evidence of proliferating progenitor cells, in adult hippocampal tissue. This strengthened the argument that the cellular machinery associated with neurogenesis can persist throughout adulthood. But several questions remain unanswered. Identifying neural progenitors doesn’t automatically establish how many mature, functional neurons are produced. We still don’t know the extent to which adult-born neurons integrate into existing neural circuits. Individual variability appears substantial. And perhaps most importantly, we don’t know how much adult hippocampal neurogenesis contributes to memory, learning, emotional regulation, or psychiatric health in humans. Why does this matter for nootropic research? Because claims about compounds increasing neurogenesis are everywhere. NSI-189, dihexa, various peptides, and numerous experimental compounds are frequently discussed in this context. But demonstrating increased neurogenesis in rodents is very different from demonstrating meaningful functional improvements in humans. A compound might increase neurotrophic signaling, alter progenitor activity, or improve performance in an animal model. None of those findings automatically establishes that it generates functional new neurons in the adult human brain. My takeaway: The evidence increasingly supports the persistence of neural progenitor activity in the adult human hippocampus. That’s genuinely exciting. But the next challenge isn’t simply proving these cells exist. It’s understanding what they actually do, whether their activity can be safely modified, and whether doing so produces meaningful clinical benefits. The distinction between biological plausibility and demonstrated human outcomes remains essential. Not medical advice. #Neurogenesis #Neuroscience #BrainHealth #Nootropics #Neuroplasticity #Longevity #CognitiveHealth #Pharmacology

One of the more interesting neuroprotective compounds in Russian pharmacology is something most people in the United States have probably never heard of. Emoxypine succinate, commonly marketed as Mexidol. It’s essentially a substituted hydroxypyridine ring structurally related to vitamin B6, paired with succinate. What makes this compound interesting is its proposed dual mechanism involving oxidative stress and mitochondrial energy metabolism. Let’s examine the pharmacology. 1. Antioxidant and neuroprotective activity The emoxypine component, 2-ethyl-6-methyl-3-hydroxypyridine, has demonstrated several effects in preclinical research: • Free-radical scavenging activity. • Increased superoxide dismutase (SOD) activity. • Increased glutathione peroxidase activity. • Modulation of Nrf2 signaling under ischemic conditions. These mechanisms are particularly interesting in neurological conditions involving oxidative stress and impaired cellular metabolism. 2. Mitochondrial metabolism The succinate component is relevant because succinate participates in mitochondrial energy production through complex II of the electron transport chain. Succinate also acts as a signaling molecule through SUCNR1, previously known as GPR91. In aged rats exposed to stress, emoxypine succinate was associated with normalization of cortical PGC-1α and SUCNR1 gene expression. That suggests potential effects on mitochondrial regulation, although these findings remain preclinical. What about human research? The MIR trial is one of the more compelling studies. This randomized, double-blind, placebo-controlled trial enrolled 304 patients recovering from ischemic stroke. Emoxypine succinate was administered alongside standard treatment. Researchers reported improvements in neurological function, disability assessments, and mobility compared with placebo. Cognitive outcomes showed a favorable trend but were less convincing. Adverse events occurred in approximately 23% of participants in both groups. Now the limitations. Much of the clinical literature originates from Russian research groups and Russian-language publications. A pooled analysis of 11 stroke studies included only two randomized trials. Another meta-analysis examining cognitive outcomes relied on comparisons against basic therapy rather than consistently using placebo controls. And despite its established use in Russia, Mexidol lacks FDA and EMA approval. My takeaway: Emoxypine succinate is an interesting example of a compound with plausible antioxidant and mitochondrial mechanisms, supported by some encouraging clinical research. But promising mechanisms and positive regional clinical trials aren’t substitutes for independent replication. I’d particularly like to see larger international trials examining neurological recovery, cognitive outcomes, and long-term safety. There’s enough here to justify scientific interest. Not enough to make sweeping claims about neuroprotection or cognitive enhancement in healthy individuals. Not medical advice. #Emoxypine #Mexidol #Neuroprotection #Nootropics #Neuroscience #Mitochondria #Pharmacology #Biohacking

This might be one of the most scientifically illiterate takes on creatine I’ve seen. Creatine is one of the most extensively researched supplements in sports nutrition, with decades of evidence supporting its safety and effectiveness in healthy individuals. First, creatine doesn’t inflate muscles like a balloon. It increases phosphocreatine availability, improving ATP regeneration during high-intensity exercise. The increased water retention is primarily intracellular, not some imaginary inflation of muscle tissue. Second, creatine improves strength, power output, training capacity, and lean mass gains when combined with resistance training. These are measurable physiological adaptations, not cosmetic illusions. Third, the claim that creatine causes soft tissue injuries because muscles lack “pure substance” is completely fabricated. Research doesn’t support an increased risk of muscle strains, tendon injuries, or cramping. Some athletic studies actually report fewer injuries among creatine users. But here’s what makes this take even worse: creatine isn’t exclusively a muscle supplement. Your brain has enormous energy demands, and the creatine-phosphocreatine system helps maintain cellular ATP availability in neural tissue. Human research suggests creatine supplementation may improve certain aspects of memory and cognitive performance, particularly in older adults, vegetarians, and individuals experiencing sleep deprivation or metabolic stress. Results in healthy, well-rested young adults are less consistent. There’s also emerging research investigating creatine’s potential neuroprotective properties and applications in neurological conditions, although clinical benefits remain unproven. And here’s the funniest part: your body naturally synthesizes creatine, and you consume it through foods like meat and fish. It’s already part of normal human physiology. Nutrition and sleep are foundational. Nobody disputes that. But pretending they somehow invalidate decades of research on supplementation is ridiculous. You’re telling elite athletes to abandon one of the most evidence-supported performance supplements available while demonstrating a fundamental misunderstanding of muscle physiology, cellular energetics, and neuroscience. Creatine isn’t just about building muscle. It’s involved in maintaining energy availability in both skeletal muscle and the brain. Being loud and confident doesn’t make you scientifically literate. #Creatine #SportsScience #Neuroscience #CognitivePerformance #Biohacking

Ibutamoren (MK-677): What the Research Shows elevateresearch.blog/2026/10…

I really don’t understand this outlook. I fully support people using all available tools necessary to become healthier versions of themselves.

100% (excuse my early repost) lol

For decades, HDL has been called the “good cholesterol.” Higher HDL levels are associated with lower cardiovascular risk. So why have nearly every major pharmaceutical intervention designed to raise HDL failed to prevent heart attacks? This is one of the most fascinating examples of the difference between correlation and causation in medicine. Let’s examine the clinical evidence. Torcetrapib — ILLUMINATE (2007) Torcetrapib dramatically increased HDL cholesterol. Unfortunately, the trial was terminated early after researchers observed increased cardiovascular events and mortality. The drug improved the biomarker while worsening clinical outcomes. Off-target effects, including increased blood pressure, complicated interpretation. Dalcetrapib and Evacetrapib Both successfully increased HDL. Neither demonstrated meaningful reductions in cardiovascular events in their major outcome trials. Both programs encountered trials stopped for futility. Niacin — AIM-HIGH and HPS2-THRIVE Niacin increases HDL and improves several traditional lipid measurements. Yet neither major trial demonstrated additional cardiovascular protection when added to contemporary lipid-lowering treatment. HPS2-THRIVE also identified increased serious adverse events. Anacetrapib — REVEAL Anacetrapib finally demonstrated a modest reduction in coronary events. However, researchers attributed much of the benefit to reductions in non-HDL cholesterol rather than increased HDL itself. Now consider the genetic evidence. A 2012 Lancet Mendelian randomization study examined genetic variants associated with naturally elevated HDL. One variant increased HDL without producing the expected reduction in myocardial infarction risk. That finding challenged the assumption that simply increasing HDL cholesterol should reduce cardiovascular events. So what does this actually tell us? HDL cholesterol is associated with cardiovascular health, but its concentration doesn’t necessarily reflect the functionality of HDL particles. Higher HDL frequently accompanies favorable metabolic characteristics, including lower triglycerides and improved insulin sensitivity. It may serve partly as a marker of metabolic health rather than a direct therapeutic target. That doesn’t mean HDL biology is irrelevant. HDL participates in reverse cholesterol transport, inflammation regulation, and other potentially protective processes. But increasing the number on a laboratory report doesn’t automatically improve those functions. My takeaway: This is why I find pharmacology and drug development so fascinating. A mechanism can make perfect biological sense. A medication can successfully manipulate its intended biomarker. And the clinical outcome can still be completely different from what researchers predicted. It’s also why ApoB and the burden of atherogenic lipoproteins deserve so much attention in cardiovascular risk assessment. Improving a biomarker isn’t necessarily the same as improving health outcomes. Sometimes the marker is associated with protection without being the mechanism responsible for it. Research: ILLUMINATE (2007), AIM-HIGH (2011), HPS2-THRIVE (2014), REVEAL (2017), Lancet Mendelian Randomization (2012). Not medical advice. #HDL #Cholesterol #ApoB #CardiovascularHealth #LipidResearch #Pharmacology #Longevity #MetabolicHealth

What if the food you’re eating influences how much you consume, even when calories, protein, carbohydrates, fat, sugar, and fiber are matched? That’s exactly what researchers at the NIH investigated in one of the most interesting controlled nutrition studies published. Hall et al., Cell Metabolism (2019). Researchers recruited 20 adults who lived inside the NIH Clinical Center for four weeks. Participants spent two weeks eating an ultra-processed diet and two weeks eating a minimally processed diet, in randomized order. Both diets were matched for calories offered, macronutrients, sugar, sodium, and fiber. Participants could eat as much or as little as they wanted. The results were significant. During the ultra-processed diet: • Participants consumed approximately 500 additional calories daily. • Body weight increased by roughly 2 pounds. • Participants ate faster and consumed more calories per minute. During the minimally processed diet: • Participants spontaneously reduced calorie intake. • Body weight decreased by approximately 2 pounds. Nobody instructed participants to overeat or restrict calories. The food environment itself influenced consumption. Why is this research important? Most nutritional research relies heavily on observational data and self-reported food intake. This was a randomized inpatient experiment where researchers controlled the food environment and directly measured consumption. That provides considerably stronger evidence for a causal relationship. But there are limitations. The study included only 20 participants, with each dietary intervention lasting two weeks. It also doesn’t establish which specific characteristics of ultra-processed foods drove the increased consumption. Energy density, texture, eating speed, palatability, and food structure are all potential contributors. And importantly, this doesn’t mean every packaged or processed food is inherently unhealthy. My takeaway: We spend enormous amounts of time discussing calorie deficits, discipline, and willpower. But this research demonstrates that food selection itself can substantially influence spontaneous calorie intake. The same individuals, with the same freedom to eat, consumed approximately 500 additional calories daily simply because the dietary environment changed. Calories still determine energy balance. But the foods we choose can influence how easily we maintain that balance. That’s an important distinction, especially when discussing obesity treatment and long-term weight management. Research: Hall et al., Cell Metabolism (2019). #NutritionScience #MetabolicHealth #ObesityResearch #UltraProcessedFoods #WeightManagement #Longevity

AOD-9604: What the Research Shows elevateresearch.blog/2026/10…

KPV: What the Research Shows elevateresearch.blog/2026/10…